Nitroglycerin Versus Terbutaline for Intrapartum Fetal Resuscitation
Information source: Stanford University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Fetal Distress
Intervention: Terbutaline (Drug)
Phase: N/A
Status: Completed
Sponsored by: Stanford University Official(s) and/or principal investigator(s): Yasser Yehia El-Sayed, Principal Investigator, Affiliation: Stanford University
Summary
To compare nitroglycerin and terbutaline for intrapartum fetal heart rate resuscitation
Clinical Details
Official title: Nitroglycerin Versus Terbutaline for Intrapartum Fetal Resuscitation
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: resolution of abnormal fetal heart tracing
Secondary outcome: cesarean section rateoperative vaginal delivery rate neonatal outcomes
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria::
- nonreassuring fetal heart rate tracing
Exclusion Criteria:- maternal cardiac disease, placental abruption, intrauterine growth
restriction, prior cesarean section
Locations and Contacts
Stanford University School of Medicine, Stanford, California 94305, United States
Additional Information
American Journal of Obstetrics and Gynecology. 2007 Oct;197(4):414.el-6
Starting date: October 2003
Last updated: March 4, 2011
|